Share This

Related Topics News -

     
 < Previous page   Title only   |   Print 
     
加科思Pan-KRAS抑制劑JAB-23E73新藥臨床實驗申請獲美國批准

2024-09-23T  
《業績》加科思中期虧損微擴至1.69億人民幣

2024-09-01T  
加科思與一間藥企就旗下兩款藥物訂立獨家對外許可協議

2024-08-30T  
加科思完成JAB-3312與Glecirasib聯用註冊性三期臨床研究首例患者給藥

2024-08-07T  
加科思擬斥1億元回購股份

2024-06-11T  
加科思在ASCO大會口頭報告兩項臨床數據

2024-06-02T  
加科思抑制劑新藥內地上市申請獲受理

2024-05-22T  
加科思抑制劑治療結直腸癌註冊性三期臨床研究獲批

2024-05-12T  
 < Previous page 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.